

ANNEXIN LEVELS IN PATIENTS WITH ACANTOLYTIC PEMPHIGUES WITH GLUCOCORTICOSTEROID RESISTANCE

About the author:	Kutasevych Ya.F., Oliynyk I.O., Abdalla A.E.-S.E.-S., Gavryushenko A.S.
Heading	ORIGINAL RESEARCHES
Type of article	Scientific Article
Annotation	<p>Objective. To investigate the level of annexin A1 in patients with acantholytic pemphigus (AP) depending on the state of steroid resistance (SR) and the dose of systemic glucocorticosteroids (SGCs).</p> <p>Materials and methods of the study. The study involved 33 patients aged 29 to 73 years with a diagnosis of AP, confirmed clinically and laboratory. The dose of SGCS in patients was converted to the equivalent of prednisolone. The state of steroid resistance (SR) was assessed by the resistance index (RI). Patients were divided into steroid-sensitive (SR) and steroid-resistant (SR) according to the results of the IR, which ranged from 1 to 12 points. The concentration of annexin A1 (ANXA1) was determined by ELISA.</p> <p>Results. The study determined the level of ANXA1 in the serum of patients with AP depending on the dose of GCS and steroid sensitivity. The results showed that the level of ANXA1 was increased at the beginning of therapy and at the maintenance dose of GCS, and before treatment the level of ANXA1 corresponded to the values of the control group. In patients with steroid sensitivity (MS) at the average dose of GCS, the level of ANXA1 was (0.82±0.09) ng/ml, while in steroid-resistant (SR) patients it was higher – (1.18±0.13) ng/ml. Reducing the dose of SGCS in the MF group reduced the level of ANXA1 to the control group (0.46±0.11) ng/ml, while in the SR group the level of ANXA1 remained elevated (0.68±0.11) ng/ml.</p> <p>Conclusions. Thus, in all patients with AP at the beginning of therapy, a significant increase in ANXA1 levels was noted and their decrease when the maintenance dose was reached. The average daily maintenance dose of SGCS was 1.57 times higher in the SR group of patients compared with this indicator in the MF group.</p>
Tags	<i>pemphigus vulgaris, diagnostics, systemic glucocorticosteroids, steroid resistance, annexin.</i>
Bibliography	<ol style="list-style-type: none"> 1. Abdalla A. E-S. E-S. Steroid resistance and annexin a1 level in patients with acantholytic pemphigus. Current problems of modern medicine: Bulletin of the Ukrainian Medical Stomatological Academy. 2022; 22(3–4): 29–34. 2. Hannon R., Croxtall J. D., Getting S. J. et al. Aberrant inflammation and resistance to glucocorticoids in annexin 1–/– mouse. The FASEB Journal. 2003; 17 (2): 253–255. 3. Girol A. P., Mimura K. K.O., Drewes C. C. et al. Anti-inflammatory mechanisms of the annexin A1 protein and its mimetic peptide Ac2–26 in models of ocular inflammation in vivo and in vitro. Journal of Immunology. 2013; 190 (11): 5689–5701. 4. Kutasevych Ya., Oliynyk I., Abdalla A. Clinical and molecular genetic parallels of steroid resistance of acantholytic pemphigus. Proceedings of the 6th International Scientific and Practical Conference «Current Issues and Prospects for the Development of Scientific Research» (October 19–20, 2022; Orleans, France). Scientific Collection «InterConf+». No. 26 (129). Orleans (France): Epi, 2022: 260–269. 5. Laxminarayana D. Is Tolerance Broken in Autoimmunity? Clin Med Insights Pathol. 2017; 10. Article ID1179555717712716. 6. Musso G., Cassader M., Gambino R. Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies. Nat. Rev. Drug Discov. 2016; 15(4): 249–274. 7. Purvis G. S.D., Solito E., Thiernemann C. Annexin-A1: Therapeutic Potential in Microvascular Disease. Frontiers in immunology. 2019; 10. Article ID938.

8. Kutasevych Ya., Abdalla A., Oliinyk I., Mashtakova I., Shcherbakova. Y. Retrospective chart analysis of patients diagnosed with acantholytic pemphigus for the period 2008–2018. Wiadomości Lekarskie. 2022; 75 (2): 416–421.

Publication of the article	«DERMATOLOGY AND VENEREOLOGY» №4(110), 2025 year, 12-15 pages,
DOI	10.33743/2308-1066-2025-4-12-15